🧬 Aging Wiki

chronic-venous-disease

Properties1
aliasesvaricose veins, chronic venous insufficiency, CVI, chronic venous disease, CVD, venous reflux, venous hypertension, venous stasis, lower-limb venous disease

23 min read

Chronic venous disease (varicose veins / CVI)

Chronic venous disease (CVD) is the umbrella for the spectrum of lower-limb pathology caused by venous valve incompetence and sustained ambulatory venous hypertension — running from telangiectasias and reticular veins, through visible bulging varicose veins, to oedema, skin changes, and venous leg ulcers. It is one of the most common manifestations of vascular aging, and the venous counterpart to arterial-stiffening: where arterial aging is dominated by elastin fragmentation and collagen crosslinking in a high-pressure conduit, venous aging is dominated by valve degeneration plus vein-wall extracellular-matrix (ECM) remodeling in a low-pressure capacitance system. The visible bulging vein with a heaviness/pressure sensation is the classic CEAP C2 presentation and the symptom that most often brings the disease to attention.12

The disease is graded by the CEAP classification (Clinical–Etiology–Anatomy–Pathophysiology), whose clinical axis is the workhorse:

CEAP classClinical finding
C0No visible/palpable venous disease
C1Telangiectasias or reticular veins (spider veins)
C2Varicose veins (the bulging, ropey, ≥3 mm subcutaneous veins)
C3Oedema
C4Skin changes — pigmentation/eczema (C4a), lipodermatosclerosis/atrophie blanche (C4b)
C5Healed venous ulcer
C6Active venous ulcer

In the population-based Bonn Vein Study (enrolled n=3072, ages 18–79; prevalence analysis n=3016 after missing-data exclusions), the highest-stage CEAP distribution was C0 9.6% · C1 59.0% · C2 14.3% · C3 13.5% · C4 2.9% · C5–C6 0.7% — i.e., reticular/spider veins are near-ubiquitous, frank varicose veins affect ~1 in 7, and advanced skin disease/ulceration is uncommon but not rare.3

Epidemiology and aging relationship

CVD is strongly age-dependent, which is the core reason it belongs in an aging wiki rather than a purely vascular-surgery context.

  • Prevalence (Edinburgh Vein Study, n=1566, ages 18–64). Age-adjusted trunk varicose veins 40% in men / 32% in women; CVI 9% in men / 7% in women; over 80% had at least mild reticular/hyphenweb veins. All categories of varices and CVI increased with age (p≤0.001).4 (Note: this study found men > women for trunk varices, reversing the classic teaching — see risk factors.)
  • Incidence and age gradient (Edinburgh, 13.4-yr follow-up). 13-year cumulative incidence of C2 varicose veins 18.2% (~1.4%/yr), rising monotonically with age from 9.8% (18–34 yr) to 25.7% (55–64 yr) (p<0.001); 13-year CVI incidence 9.2% (~0.7%/yr).5
  • CEAP / reflux with age (Bonn). Pathologic reflux (>500 ms) in 35.3% overall; superficial-vein reflux increases markedly with age, whereas deep-system reflux shows no clear age trend — i.e., the superficial venous system is the one that fails with aging.3
  • Sex (San Diego Population Study, multiethnic, n=2211, duplex-based). Women had higher odds of varicose veins (OR 2.18) and spider veins (OR 5.36), but trophic skin changes and deep functional disease were less common in women (OR 0.65). These are age- and ethnicity-adjusted prevalence ORs from multiple logistic regression; CIs were not reported in the published table.6

Genetics and heritability

Varicose veins are strongly familial but genetically complex. Classical twin/family heritability is high — a twin study estimated ~86%7 — yet the common-variant heritability captured by GWAS is far lower (Fukaya 2018 LDSC SNP-based h²≈0.28 on the liability scale; the ~13–17% figures quoted elsewhere are SNP-based estimates), a wide gap that is the classic missing-heritability signature of a polygenic architecture: many small-effect loci, no single major gene. The practical upshot — a strong family pattern is fully expected and consistent with the genetics, but it does not point to one identifiable mutation. Family history is a robust risk factor (incidence OR ~1.75, Edinburgh5), but the inherited risk is spread across many loci of small effect: the Fukaya 2018 GWAS found 30 genome-wide-significant loci,8 a 2022 meta-analysis in 810,625 individuals extended this to 49 signals at 46 loci,9 and a 2026 systematic review of venous-disease GWAS (13 GWASs, 602,760 VV patients) catalogues the convergent loci across studies, confirming STIM2, EBF1, GATA2 (itself a valve-development gene), CASZ1, and PIEZO1 as the most replicated signals.10 Implicated pathways: vascular/valve development, mechanosensation (PIEZO1), connective tissue (fibrillin), and the calcineurin/NFAT axis (PPP3R1) — see the developmental-program detail and the varicose-vein ↔ cardiac-valve genetic bridge on veins.

Rare Mendelian forms exist and are the exception that turns this into a single-gene disease: FOXC2 (the venous-valve transcription factor) — a frameshift mutation (881’inT) has been reported in a family with both varicose veins and hemorrhoids (low-impact, non-PubMed-indexed source; treat as preliminary),11 a promoter variant (c.-512C>T) is associated with CVD susceptibility (OR 2.08),12 and the FOXC2 chromosomal region shows significant linkage to varicose veins (but not independently to hemorrhoids) in unselected sibling pairs;7 EPHB4 loss-of-function causes venous valve aplasia.13 These are flagged clinically by very early onset, severity, and syndromic features, not ordinary adult-onset disease.

Genetic testing — what it can and can’t do. Consumer SNP arrays (e.g., 23andMe) do not report a varicose-vein result, but the raw genotype data can be run through a polygenic risk score — the PGS Catalog hosts published varicose-vein scores14 — yielding a research-grade relative-risk percentile, not a diagnosis. Arrays cannot reliably detect rare FOXC2/EPHB4 variants. Whole-exome/genome sequencing detects rare Mendelian variants and supports a fuller PRS, but diagnostic yield for isolated varicose veins is low, and identifying a family-specific causal variant would require sequencing multiple affected relatives to find a co-segregating variant — a single proband’s genome cannot isolate “the family variant” for a polygenic trait. None of this is clinically actionable: management is driven by the duplex + symptom phenotype, not genotype.

Mechanisms — multi-hallmark venous aging

The pathophysiology is a self-reinforcing loop: valve failure → reflux → venous hypertension → vein-wall and valve damage → more valve failure. Aging enters this loop at multiple points.

1. Valve incompetence and ambulatory venous hypertension (the hemodynamic core)

Competent bicuspid venous valves and the calf muscle pump (skeletal-muscle) normally keep ambulatory venous pressure in the foot low (~30 mmHg during walking). When valves become incompetent, blood refluxes distally under gravity, and ambulatory venous pressure stays pathologically elevated (ambulatory venous hypertension). Sustained hypertension dilates the vein, separates the valve cusps further, and propagates incompetence to adjacent segments — a descending or ascending cascade depending on the initiating segment. This hemodynamic mechanism is the spine of every modern review.12 The orthostatic pressure column is why this is a bipedal, gravity-loaded human disease (see Extrapolation).

2. Vein-wall ECM remodeling: the MMP/TIMP imbalance

The dilated, tortuous varicose vein is not just a stretched normal vein — its wall is biochemically remodeled. Elevated venous hydrostatic pressure, hypoxia, and inflammation upregulate matrix metalloproteinases (MMPs) — notably mmp-1, mmp-2, mmp-3, and MMP-7 (with MMP-2 activity specifically elevated, and MMP-9 enriched in endothelial cells and medial VSMCs) — which degrade collagen and elastin, weakening the wall and disrupting the elastic recoil that resists dilation. The balance with their inhibitors (timp-1 and other TIMPs) is shifted toward net proteolysis. Beyond structural breakdown, MMP activity also drives venous relaxation/dilation directly via endothelium-derived hyperpolarizing mediators and K⁺-channel activation in smooth muscle, linking ECM proteolysis to the dilation phenotype.1516 This MMP-driven loss of elastin and disordered collagen is the venous analogue of the ECM derangement in arterial-stiffening, and ties the phenotype to altered-intercellular-communication (SASP-associated ECM turnover; see sasp).

3. Hypoxia, mechanotransduction, and inflammation

Prolonged mechanical stretch of the vein wall upregulates hypoxia-inducible factors (HIFs) and reduces contractility — shown experimentally by sustained stretch of rat inferior vena cava, providing a mechanistic bridge from venous hypertension/distension to a hypoxic, pro-remodeling wall state.17 Venous hypertension also triggers leukocyte–endothelial adhesion and a chronic inflammatory infiltrate (glycocalyx disruption, leukocyte trapping), which both endothelial dysfunction and the downstream skin damage of CVI depend on — connecting the phenotype to chronic-inflammation and inflammaging.12 Endothelial and fibroblast cellular-senescence plausibly amplifies the SASP-driven, MMP-rich wall environment, though direct senescence-specific causal data in human varicose veins is thinner than the mechanistic-plausibility case (see gaps).

Clinical relevance and downstream consequences

  • Symptoms: aching, heaviness, pressure, throbbing, night cramps, itching, restless legs — typically worse with prolonged standing and at day’s end, relieved by elevation/walking. Symptom burden correlates poorly with vein size; small veins can be very symptomatic and large ones silent.2
  • Progression cascade (Edinburgh, 13.4-yr). 57.8% of affected legs progressed over follow-up (~4.3%/yr); of legs with varicose veins only at baseline, 31.9% developed CVI, with progression risk rising with age. Independent progression risk factors: family history (OR ~1.85), prior DVT (OR 4.10), overweight, and combined superficial+deep reflux.18
  • Endpoint: the C6 venous leg ulcer is the costly, morbid terminus, driven by sustained venous hypertension → skin inflammation → lipodermatosclerosis → ulceration.1

Interventions

Graded by evidence quality — note the sharp split between strong procedural evidence and weak-to-modest conservative/pharmacological evidence.

Conservative — first-line, but weak trial support

  • Graduated compression stockings. Despite universal first-line use, a Cochrane review (13 RCTs, n=1021, 10–50 mmHg) found only low-to-very-low-certainty evidence for varicose veins without ulcer; symptom improvement is reported but bias-prone, and effectiveness versus no compression could not be established.19 Compression has stronger evidence in the distinct setting of venous ulcer healing. dose-response-unclear
  • Calf-muscle-pump activation (walking/exercise), leg elevation, weight management. Mechanistically sound (the calf pump is the physiological antagonist of venous hypertension) and low-risk; weight/obesity is a modifiable risk factor (CVI OR 3.58 in Edinburgh). What the RCT evidence actually shows: (a) structured calf exercise improves calf-pump hemodynamics — a small RCT (n=31, CEAP 4–6, all on class II compression, 30–40 mmHg) found increased ejection fraction (3.48±2.7 vs −1.4±2.1, P<.026) and decreased residual volume fraction (P<.029) at 6 months, but reflux was unchanged in both groups20 — i.e., exercise strengthens the compensatory pump, it does not correct the underlying valve reflux; (b) as an adjunct to compression, exercise improves venous-leg-ulcer (C6) healing — meta-analysis of 7 RCTs (n=246), pooled healing RR 1.38 (95% CI 1.11–1.71), absolute risk difference +18 healed per 100 patients (95% CI 7–30).21 A corroborating 2023 meta-analysis (8 RCTs, n=270) found pooled RR 1.38 (95% CI 1.14–1.66).22 What no RCT has shown is that exercise slows structural progression of varicose veins / CVD (no trial uses incidence or CEAP-progression endpoints; trials are small, short, and surrogate/symptom-focused). So exercise is worthwhile for symptoms, pump function, and ulcer healing — but progression-prevention is unproven, consistent with the broader point that no intervention (including ablation) has RCT proof of preventing early-stage progression. needs-replication

Venoactive (phlebotonic) drugs — modest, oedema-only

  • Phlebotonics broadly (micronized purified flavonoid fraction / diosmin-hesperidin, rutosides, calcium dobesilate, pycnogenol). Cochrane (69 RCTs, 56 with usable data, n=7690): moderate-certainty that they probably reduce oedema slightly (RR 0.70, 95% CI 0.63–0.78) and ankle circumference (MD −4.27 mm), but little/no effect on quality of life, and no effect on ulcer healing (RR 0.94, 95% CI 0.79–1.13); probably increase adverse events.23 The benefit is real but small and confined to oedema/symptoms — not disease modification.
  • Horse chestnut seed extract (escin). Cochrane: short-term reductions in leg pain and leg volume (WMD 32.1 mL reduction favouring HCSE, 95% CI 13.49 to 50.72; 6 trials, n=502); judged “efficacious and safe for short-term treatment of CVI,” but calling for larger definitive RCTs.24 Full mechanism, dose, and safety on escin. long-term-unknown

Procedural / interventional — strongest evidence

For symptomatic truncal reflux (e.g., great saphenous vein incompetence), endovenous techniques have largely replaced open surgery:

  • Endovenous thermal ablation — endovenous laser ablation (EVLA) and radiofrequency ablation (RFA): catheter-delivered thermal closure of the refluxing trunk.
  • Ultrasound-guided foam sclerotherapy (UGFS) — chemical obliteration; lower upfront cost but inferior durability/QoL in head-to-head data.
  • Non-thermal non-tumescent: cyanoacrylate closure (VenaSeal; non-inferior to RFA at 12 and 36 months in VeClose) and mechanochemical ablation (MOCA).
  • Surgery — high ligation + stripping; still effective but more invasive.

The landmark comparative-effectiveness data:

  • CLASS trial (n=798, UK). At 5 years, disease-specific QoL (Aberdeen Varicose Vein Questionnaire) was better with laser and surgery than with foam (laser vs foam adjusted difference −2.86, 95% CI −4.49 to −1.22, P<0.001); laser was the most cost-effective (favored in 77.2% of model iterations at £20,000/QALY).2526
  • EVRA trial (n=450). In patients with venous leg ulcers, early endovenous ablation accelerated ulcer healing (HR for healing 1.38, 95% CI 1.13–1.68, P=0.001; median time to healing 56 vs 82 days) versus deferred treatment — the strongest randomized demonstration that intervention alters the disease’s worst endpoint.27
  • VeClose — cyanoacrylate closure non-inferior to RFA.28
  • Comparative systematic review across all modalities for GSV incompetence: Cochrane CD005624.29

Current management is codified in the ESVS 2022 and SVS/AVF/AVLS 2023 clinical practice guidelines.3031

For the distinct and harder problem of deep-system reflux / post-thrombotic syndrome — which superficial ablation does not address — surgical valve repair and artificial (bioprosthetic) venous valves are covered on venous-valve-reconstruction. The detailed venous-valve anatomy/development/failure biology (and its comparison to heart valves) is on veins.

Hypothesized progression-slowing strategies (open question)

This section is mechanism-grounded hypothesis, not established evidence. No intervention has RCT proof of slowing CVD progression (see Interventions and Limitations). It reasons forward from the verified disease loop above; each candidate is flagged for the evidence it lacks. New factual anchors not elsewhere on the wiki are tagged #gap/needs-verification.

Progression is driven by a self-reinforcing loop — reflux → ambulatory venous hypertension → vein-wall MMP/ECM degradation + valve-sinus inflammation + EndMT (± senescence/SASP) → more dilation and valve failure → more reflux (Mechanisms). Candidate disease-modifiers map to where they would break the loop:

1. Break the hemodynamic driver (strongest rationale; partly available now). Lowering time-integrated ambulatory venous hypertension is upstream of all tissue damage. The modifiable levers: early/habitual compression, weight loss (obesity CVI OR 3.585), calf-pump activation (improves pump hemodynamics, though not reflux20), leg elevation. The boldest testable idea is early endovenous ablation of the refluxing source at C2 to interrupt the loop before it amplifies: EVRA showed early ablation accelerates ulcer healing,27 but whether it prevents C2→C3+ progression is untested — no trial has evaluated early ablation at C2 using progression (rather than ulcer-healing) endpoints. needs-replication

2. Interrupt the wall-remodeling response (repurposing candidates, untested in CVD).

  • MMP inhibition — the MMP/TIMP imbalance is the molecular engine of wall dilation;15 sub-antimicrobial doxycycline is an off-the-shelf MMP inhibitor (tempering note: it largely failed in the analogous MMP-driven abdominal aortic aneurysm). needs-human-replication needs-verification
  • Endothelial / glycocalyx protection — sulodexide (a glycosaminoglycan with endothelial-protective, anti-inflammatory action and existing venous-ulcer trial signal) maps onto the valve-sinus antithrombotic endothelial program (veins). needs-verification
  • Venoactive flavonoids (MPFF/diosmin) reduce leukocyte adhesion + oedema but have shown no disease-modification.23

3. Aging-biology frontier (speculative; aligned with the hallmark mapping). CVD maps to cellular-senescence + chronic-inflammation + altered-intercellular-communication. By analogy to arterial-stiffening — where senolytics reduced pulse-wave velocity in aged mice — senolytics/senomorphics could in principle quiet the SASP→MMP→remodeling drive in the vein wall (zero venous data). EndMT inhibition (EndMT is reactivated in varicose veins — see veins) and modulation of the PROX1/FOXC2/calcineurin–NFAT valve-maintenance program (PPP3R1 is a GWAS hit; PROX1 protects valves) are target-discovery leads, not interventions. no-mechanism

Meta-point: the most defensible and most-testable hypotheses are hemodynamic and early (lower venous pressure; abolish reflux before the loop amplifies). The field’s central gap is the absence of any RCT using progression endpoints — an early-ablation-at-C2 trial measuring C2→C3+ progression has not been done.

Hallmark mapping

CVD is a multi-hallmark phenotype that overlaps mechanistically with arterial vascular aging:

  • altered-intercellular-communication — the central ECM-remodeling axis: MMP/TIMP imbalance degrading elastin and collagen, plausibly amplified by sasp from senescent vessel-wall cells. This is the dominant hallmark for the vein-wall phenotype.
  • chronic-inflammation — venous-hypertension-driven leukocyte–endothelial adhesion and chronic wall/skin inflammation; inflammaging as a permissive background.
  • cellular-senescence — endothelial and fibroblast senescence as a plausible (mechanism-strong, human-data-thin) amplifier of the SASP/MMP-rich wall environment.

It is a sibling of arterial-stiffening under the cardiovascular-aging umbrella, sharing the elastin-loss/ECM-remodeling theme but diverging in hemodynamics (low-pressure capacitance + gravity-loaded valves vs high-pressure conduit).

Extrapolation from model organisms

Varicose veins are largely a human-specific phenotype, which is itself an important evidence caveat — quadrupedal model organisms do not experience the bipedal orthostatic venous-pressure column that drives the disease.

DimensionStatus
Pathway conserved in rodents?Partial. The molecular machinery (MMP/TIMP ECM remodeling, HIF/stretch mechanotransduction, leukocyte–endothelial inflammation) is conserved and is studied in rodent vein-wall/IVC models.1715
Phenotype conserved (spontaneous varicose veins)?No. Quadrupeds do not develop spontaneous gravity-driven lower-limb varicose veins; there is no good spontaneous animal model. no-mechanism (animal model)
Replicated/modeled in humans?Yes — the disease is human; mechanism is studied directly in excised human varicose-vein wall and via human duplex hemodynamics, so the “extrapolation” runs from surrogate animal stretch/ligation models to the human disease, not the usual direction.12

Limitations and gaps

  • Age-related decline in venous valve number/competence is described narratively across the major reviews but a single primary paper quantifying valve loss with age was not located with a verifiable identifier in this draft. needs-replication unsourced
  • Senescence-specific causal evidence in human varicose veins (vs mechanistic plausibility) is thin; the cellular-senescence link is inferred from the broader vascular-aging literature. no-mechanism
  • No RCT demonstrates that treating early-stage (C2) varicose veins prevents progression to CVI/ulcer; the progression data is observational (Edinburgh) and the procedural RCTs measured QoL or ulcer healing, not primary prevention of progression. contradictory-evidence
  • MOCA landmark RCTs (e.g., LAMA, MARADONA) and the CEAP-definition primary paper (Eklöf 2004 revision) and NICE CG168 are referenced generically; their exact identifiers were not verified in this draft. needs-replication
  • Conservative-therapy evidence (compression, exercise) is low-certainty; phlebotonic benefit is modest and oedema-confined. dose-response-unclear

Footnotes

Footnotes

  1. doi:10.1056/NEJMra055289 · Bergan JJ et al. · N Engl J Med 2006;355(5):488–498 · review (landmark) · PMID 16885552 · valve incompetence → reflux → ambulatory venous hypertension → leukocyte–endothelial inflammatory cascade; foundational mechanistic synthesis ↩ ↩2 ↩3 ↩4 ↩5

  2. doi:10.1161/CIRCULATIONAHA.113.006898 · Eberhardt RT, Raffetto JD · Circulation 2014;130(4):333–346 · review · PMID 25047584 · updated hemodynamic/clinical mechanism review (CVI); supersedes their 2005 Circulation review (PMID 15883226) ↩ ↩2 ↩3 ↩4 ↩5

  3. doi:10.1016/j.jvs.2008.04.029 · Maurins U et al. (Bonn Vein Study) · J Vasc Surg 2008;48(3):680–687 · observational, population-based · enrolled n=3072, analysis n=3016, ages 18–79 · CEAP highest-stage distribution C0 9.6/C1 59.0/C2 14.3/C3 13.5/C4 2.9/C5–6 0.7%; overall pathological reflux (>500 ms) 35.3% (95% CI 33.6–37.1); superficial reflux 21.0% (95% CI 19.5–22.5); deep reflux 20.0% (95% CI 18.6–21.5); superficial reflux rises markedly with age, deep reflux shows no clear age trend · PMID 18586443 ↩ ↩2

  4. doi:10.1136/jech.53.3.149 · Evans CJ et al. (Edinburgh Vein Study) · J Epidemiol Community Health 1999;53(3):149–153 · observational, cross-sectional · n=1566 (867W/699M), ages 18–64 · age-adjusted trunk varices (grades 1–3) 39.7% M / 32.2% W (abstract rounds to 40%/32%; p≤0.01); CVI 9.4% M / 6.6% W (abstract rounds to 9%/7%; p≤0.05); >80% had mild hyphenweb/reticular varices; all categories increase with age p≤0.001; no social-class relationship · PMID 10396491 ↩

  5. doi:10.1016/j.jvsv.2012.05.006 · Robertson L et al. (Edinburgh Vein Study) · J Vasc Surg Venous Lymphat Disord 2013;1(1):59–67 · observational, 13.4-yr follow-up · n=880 · 13-yr C2 incidence 18.2% (1.4%/yr), rising 9.8%→25.7% with age (p<0.001); CVI incidence 9.2%; obesity CVI OR 3.58 (1.70–7.56); family history VV OR 1.75 · PMID 26993896 ↩ ↩2 ↩3

  6. doi:10.1093/aje/kwg166 · Criqui MH et al. (San Diego Population Study) · Am J Epidemiol 2003;158(5):448–456 · observational, multiethnic, duplex-based · n=2211 · women vs men varicose veins OR 2.18, spider veins OR 5.36; trophic skin changes less common in women (OR 0.65); CIs not published in table; age- and ethnicity-adjusted ORs; disease increases with age · PMID 12936900 ↩

  7. doi:10.1136/jmg.2004.022293 · Ng MYM, Andrew T, Spector TD, Jeffery S; Lymphoedema Consortium · J Med Genet 2005 Mar;42(3):235–9 · PMID 15744037 · PMC1736007 · significant linkage to FOXC2 region (chr 16q24) for varicose veins in unselected dizygotic sibling pairs: MLS(ASP)=1.37 p=0.01; GLM(ASP/DSP) Z=3.17 p=0.002; VV heritability 86% (95% CI 73–99%); note: linkage and association tests for hemorrhoids at the FOXC2 locus were NEGATIVE in this paper — the hemorrhoid connection in 11 comes from a separate 2020 case report ↩ ↩2

  8. doi:10.1161/CIRCULATIONAHA.118.035584 · Fukaya E et al. · Circulation 2018;138(25):2869–2880 · GWAS + Mendelian randomization (UK Biobank) · ML/observational analyses n=493,519; GWAS n=337,536 (9,577 cases, 327,959 controls) · 30 new GWAS loci; confirmed age/female sex/obesity/pregnancy/prior DVT; height novel + causal (Cox HR upper vs lower quartile 1.74, 95% CI 1.51–2.01, P<0.0001; MR IVW OR 1.26, P=2.07×10⁻¹⁶; MR 95% CI not separately reported) · PMID 30566020 · PMC6400474 ↩

  9. doi:10.1038/s41467-022-30765-y · Ahmed WU, Kleeman S et al. (Oxford / 23andMe) · Nat Commun 2022 Jun 2;13(1):3065 · GWAS meta-analysis + replication · PMID 35654884 · PMCID PMC9163161 · n=810,625 (401,656 UK Biobank + 408,969 23andMe; 135,514 cases + 675,111 controls) · 49 signals at 46 susceptibility loci; pathway enrichment: ECM, inflammation, (lymph)angiogenesis, VSMC migration; PRS predictive utility demonstrated · heritability ~17% stated as background in abstract (source of figure not attributed inline; Fukaya 2018 LDSC reports h²=0.28 by a different method) ↩

  10. doi:10.1016/j.jvsv.2025.102365 · Soh CL, Tan M, Davies AH, Onida S (Imperial College London) · J Vasc Surg Venous Lymphat Disord 2026 Mar;14(2):102365 · systematic review (PRISMA; 13 GWASs after screening 517 studies) · PMID 41391741 · PMCID PMC12830204 · 602,760 VV patients across studies · catalogues varicose-vein susceptibility loci across GWASs: inflammation/immunity (PPP3R1, EBF1, GATA2), hypertension (CASZ1), vascular architecture (CASZ1, PIEZO1, STIM2); protective variants in Finnish populations (GJD3, MMP10, 4EBP1) · key conclusion: these polymorphisms are not generalizable across populations; larger globally representative meta-analyses needed · note: Soh is a review cataloguing loci already identified in primary GWASs (incl. Fukaya 2018, Shadrina 2019, Ahmed 2022); the framing “adds STIM2/EBF1/GATA2” in the prose overstates novelty — these were in prior GWASs; Soh confirms cross-GWAS consistency ↩

  11. doi:10.46300/91011.2020.14.5 · International Journal of Biology and Biomedical Engineering 2020;14 · “Truncating Mutation in FOXC2 Gene in Familial Hemorrhoids and Varicose Veins” · frameshift mutation 881’inT reported in two affected family members, producing premature stop codon (294-residue truncated peptide) · NOT indexed in PubMed (no PMID); publisher: North Atlantic University Union (NAUN) — low-impact, non-MEDLINE journal; PDF in Greek; exercise caution citing for clinical claims · low-evidence-source ↩ ↩2

  12. doi:10.1371/journal.pone.0090682 · Surendran S, Girijamma A, Nair R et al. · PLoS One 2014 Mar 7;9(3):e90682 · PMID 24608096 · PMC3946558 · FOXC2 promoter variant c.-512C>T (rs34221221): TT homozygotes vs CC had adjusted OR 2.08 (95% CI 1.43–3.02, p<0.001) for CVD; TT associated with elevated FoxC2 mRNA and protein, altered Notch signaling; mechanism: variant causes FoxC2 overexpression → arterial-like characteristics in venous tissue → valve dysfunction ↩

  13. doi:10.1172/jci.insight.140952 · Lyons OTA et al. · JCI Insight 2021;6(14):e140952 · human genetics · PMID 34403370 · EPHB4 loss-of-function → venous valve aplasia ↩

  14. PGS Catalog · pgscatalog.org · open database of polygenic scores · 6 published varicose-vein scores under trait HP_0002619 (“Enlarged and tortuous veins”): PGS000937, PGS000938, PGS001845, PGS002057, PGS004463, PGS004533 · verified via REST API (pgscatalog.org/rest/trait/HP_0002619) · retrieved 2026-05-25 ↩

  15. doi:10.20517/2574-1209.2021.16 · Raffetto JD, Khalil RA · Vessel Plus 2021;5:36 · review (mechanistic, comprehensive) · PMID 34250453 · MMP-1, -2, -3, -7 elevated in VVs (MMP-2 activity specifically increased); upregulated by venous pressure/hypoxia/inflammation → collagen+elastin degradation → wall weakening; MMP-2/-9 also drive dilation via BKCa-channel-mediated SMC hyperpolarization and relaxation; TIMP balance + MMP-inhibitor therapeutic candidates ↩ ↩2 ↩3

  16. doi:10.2174/157016108784911957 · Raffetto JD, Khalil RA · Curr Vasc Pharmacol 2008;6(3):158–172 · review · PMID 18673156 · MMP-driven ECM degradation → venous dilation + valve dysfunction; increased MMP activity in advanced CVI/ulceration ↩

  17. doi:10.1016/j.jvs.2010.09.018 · Lim CS et al. · J Vasc Surg 2011;53(3):764–773 · in-vivo (rat IVC) · prolonged mechanical stretch → upregulation of HIFs + reduced contraction; mechanistic stretch↔hypoxia bridge · PMID 21106323 ↩ ↩2

  18. doi:10.1016/j.jvsv.2014.09.008 · Lee AJ et al. (Edinburgh Vein Study) · J Vasc Surg Venous Lymphat Disord 2015;3(1):18–26 · observational, 13.4-yr follow-up · progression in 57.8% (~4.3%/yr); 31.9% of VV-only → CVI (age-dependent p=.04); prior DVT OR 4.10, family history OR 1.85 · PMID 26993676 ↩

  19. doi:10.1002/14651858.CD008819.pub4 · Shingler S et al. · Cochrane Database Syst Rev 2021 · systematic review · 13 RCTs, n=1021 · compression stockings (10–50 mmHg) for varicose veins w/o ulcer: low-to-very-low certainty, effectiveness vs no compression undetermined · PMID 34271595 ↩

  20. doi:10.1016/j.jvs.2003.09.036 · Padberg FT Jr, Johnston MV, Sisto SA · J Vasc Surg 2004;39(1):79–87 · RCT · PMID 14718821 · n=31 (18 exercise / 13 control), CEAP 4–6, all on class II compression (30–40 mmHg); 6-mo structured calf-strengthening exercise · ejection fraction ↑ (3.48±2.7 vs −1.4±2.1, P<.026), residual volume fraction ↓ (P<.029), calf strength ↑ — but reflux unchanged in both groups (pump function improved, underlying reflux not corrected) · verified against full abstract ↩ ↩2

  21. doi:10.1016/j.jvsv.2022.09.003 · Turner BRH, Jasionowska S, Machin M et al. · J Vasc Surg Venous Lymphat Disord 2023;11(1):219–226 · systematic review + meta-analysis · PMID 36202303 · 7 RCTs, n=246 (121 exercise / 125 compression alone), venous leg ulcers (C6); exercise as adjunct to compression · pooled healing RR 1.38 (95% CI 1.11–1.71); risk difference +18 healed per 100 patients (95% CI 7–30); no progressive-resistance subgroup (numbers insufficient) · low-certainty evidence; high risk of bias across all 7 trials · verified against full PDF ↩

  22. doi:10.1111/iwj.14020 · Zhang Q, Lu L, Song JL, Wang L · Int Wound J 2023;20(5):1776–1783 · systematic review + meta-analysis · PMID 36650634 · PMC10088832 · 8 RCTs, n=270, venous leg ulcers; exercise programs vs control · pooled healing RR 1.38 (95% CI 1.14–1.66, P=0.0008); ankle mobility SMD 0.87; pooled adherence 64% · corroborates Turner 2022 · verified against PMC full text ↩

  23. doi:10.1002/14651858.CD003229.pub4 · Martínez-Zapata MJ et al. · Cochrane Database Syst Rev 2020 · systematic review · 69 RCTs (56 usable, n=7690) · phlebotonics probably reduce oedema (RR 0.70, 95% CI 0.63–0.78) + ankle circ (MD −4.27 mm); no QoL benefit; no ulcer-healing effect (RR 0.94, 0.79–1.13); probably ↑adverse events · PMID 33141449 ↩ ↩2

  24. doi:10.1002/14651858.CD003230.pub4 · Pittler MH, Ernst E · Cochrane Database Syst Rev 2012;(11):CD003230 · systematic review · 17 RCTs · horse chestnut seed extract (escin) vs placebo: leg volume WMD 32.1 mL reduction favouring HCSE (95% CI 13.49 to 50.72; 6 trials, n=502); pain reduced in 6/7 trials; “efficacious + safe short-term,” larger RCTs needed · PMID 23152216 · sign convention corrected 2026-05-27 against full PDF (positive WMD = reduction; prior abstract-derived “−32.1 / −50.72 to −13.49” inverted the sign) — see escin ↩

  25. doi:10.1056/NEJMoa1400781 · Brittenden J et al. (CLASS) · N Engl J Med 2014;371(13):1218–1227 · RCT · n=798, 11 UK centres · laser vs foam sclerotherapy vs surgery for varicose veins · PMID 25251616 ↩

  26. doi:10.1056/NEJMoa1805186 · Brittenden J et al. (CLASS 5-yr) · N Engl J Med 2019;381(10):912–922 · RCT, 5-yr follow-up · AVVQ better for laser + surgery vs foam (laser vs foam −2.86, 95% CI −4.49 to −1.22, P<0.001); laser most cost-effective (77.2% at £20k/QALY) · PMID 31483962 ↩

  27. doi:10.1056/NEJMoa1801214 · Gohel MS et al. (EVRA) · N Engl J Med 2018;378(22):2105–2114 · RCT · n=450 · early vs deferred endovenous ablation for venous leg ulcers: HR healing 1.38 (95% CI 1.13–1.68, P=0.001); median healing 56 vs 82 days; 24-wk healing 85.6% vs 76.3% · PMID 29688123 ↩ ↩2

  28. doi:10.1016/j.jvsv.2016.12.005 · Morrison N et al. (VeClose) · J Vasc Surg Venous Lymphat Disord 2017;5(3):321–330 · RCT, 12-mo · cyanoacrylate closure (VenaSeal) non-inferior to RFA; 36-mo data PMID 30403154 · PMID 28411697 ↩

  29. doi:10.1002/14651858.CD005624.pub4 · Cochrane Database Syst Rev 2021 · systematic review · interventions for great saphenous vein incompetence (EVLA/RFA/foam/surgery comparator) · PMID 34378180 ↩

  30. doi:10.1016/j.ejvs.2021.12.024 · De Maeseneer MG et al. · Eur J Vasc Endovasc Surg 2022;63(2):184–267 · ESVS 2022 Clinical Practice Guidelines on management of CVD of the lower limbs · expert consensus guideline · corrigendum PMID 35953422 ↩

  31. doi:10.1016/j.jvsv.2023.08.011 · J Vasc Surg Venous Lymphat Disord 2023 · SVS/AVF/AVLS 2023 clinical practice guidelines for varicose veins · expert consensus guideline · PMID 37652254 ↩

Graph View

Backlinks